PMID- 11222915
OWN - NLM
STAT- MEDLINE
DCOM- 20010614
LR  - 20231213
IS  - 0165-2478 (Print)
IS  - 0165-2478 (Linking)
VI  - 76
IP  - 1
DP  - 2001 Feb 1
TI  - A clinically approved oral vaccine against pneumotropic bacteria induces the 
      terminal maturation of CD83+ immunostimulatory dendritic cells.
PG  - 63-7
AB  - Dendritic cells (DCs) are important antigen-presenting cells of the immune system 
      that have attracted interest as cellular adjuvants to induce immunity in clinical 
      settings. We have investigated the effects of Broncho-Vaxom, an oral vaccine 
      composed of lysates from eight pneumotropic bacteria, on human monocyte-derived 
      dendritic cells (moDCs). Broncho-Vaxom induced the terminal maturation of CD83+ 
      moDCs. MoDCs stimulated with Broncho-Vaxom displayed a phenotype of activated DCs 
      with high levels of major histocompatibility complex (MHC) molecules and 
      increased levels of adhesion and co-stimulatory molecules. In addition, moDCs 
      activated with Broncho-Vaxom exhibited enhanced T cell-stimulatory capacity in 
      the allogeneic mixed leukocyte reaction. Broncho-Vaxom at 100 microg/ml was as 
      potent as TNF-alpha at 1000 U/ml in activating human moDCs. Neither LPS-like 
      activity nor bacterial DNA was found to be responsible for the 
      maturation-inducing activity of Broncho-Vaxom, suggesting that Broncho-Vaxom 
      contains other bacterial factors that are capable of inducing the terminal 
      maturation of moDCs. In DC-based immunotherapy, Broncho-Vaxom could be used as a 
      stimulus of DC maturation, which meets the standards of good manufacturing 
      practice (GMP). In addition, vaccination with Broncho-Vaxom-loaded moDCs may be 
      an attractive treatment option in preventing recurrent airway infection in 
      predisposed individuals.
FAU - Zelle-Rieser, C
AU  - Zelle-Rieser C
AD  - Department of Urology, Anichstrasse 35, University of Innsbruck, A-6020, 
      Innsbruck, Austria. claudia.rieser@uibk.ac.at
FAU - Ramoner, R
AU  - Ramoner R
FAU - Bartsch, G
AU  - Bartsch G
FAU - Thurnher, M
AU  - Thurnher M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Immunol Lett
JT  - Immunology letters
JID - 7910006
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (Antigens, CD)
RN  - 0 (Bacterial Vaccines)
RN  - 0 (Broncho-Vaxom)
RN  - 0 (Cell Extracts)
RN  - 0 (Immunoglobulins)
RN  - 0 (Interferon Inducers)
RN  - 0 (Membrane Glycoproteins)
SB  - IM
MH  - Adjuvants, Immunologic/administration & dosage
MH  - Administration, Oral
MH  - Antigens, CD
MH  - *Bacteria
MH  - Bacterial Vaccines/*administration & dosage/*immunology
MH  - Cell Differentiation/immunology
MH  - *Cell Extracts
MH  - Cells, Cultured
MH  - Dendritic Cells/*cytology/*immunology
MH  - Humans
MH  - Immunoglobulins/*immunology
MH  - Immunophenotyping
MH  - Interferon Inducers/immunology
MH  - Lymphocyte Activation/*immunology
MH  - Membrane Glycoproteins/*immunology
MH  - Monocytes/cytology/immunology
MH  - Pneumonia, Bacterial/*immunology/prevention & control
MH  - T-Lymphocytes/immunology
MH  - CD83 Antigen
EDAT- 2001/02/27 10:00
MHDA- 2001/06/23 10:01
CRDT- 2001/02/27 10:00
PHST- 2001/02/27 10:00 [pubmed]
PHST- 2001/06/23 10:01 [medline]
PHST- 2001/02/27 10:00 [entrez]
AID - S0165-2478(00)00326-6 [pii]
AID - 10.1016/s0165-2478(00)00326-6 [doi]
PST - ppublish
SO  - Immunol Lett. 2001 Feb 1;76(1):63-7. doi: 10.1016/s0165-2478(00)00326-6.